Lakefront Biotherapeutics (LKFT) Liabilities from Discontinued Operations (2020 - 2023)
Lakefront Biotherapeutics (LKFT) posted quarterly Liabilities from Discontinued Operations of 34477418.44 for Q4 2023, up 270.11% quarter-over-quarter from 9315533.65 in Q1 2023.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Liabilities from Discontinued Operations (2020 - 2023) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 34477418.44 the latest figure, recorded in Q4 2023.
- In Q4 2023, Liabilities from Discontinued Operations changed N/A year-over-year to 34477418.44; the TTM figure through Dec 2023 stood at 34477418.44 (changed N/A YoY), while the FY2023 annual figure was 34477418.44, changed N/A from the prior year.
- Liabilities from Discontinued Operations rose to 34477418.44 in Q4 2023 per LKFT's latest filing, from 9315533.65 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 34477418.44 in Q4 2023 and bottomed at 9315533.65 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 34.48 Mn |
| Mar 31, 2023 | 9.32 Mn |
| Dec 31, 2020 | 10.63 Bn |